 NEW YORK, Aug. 9, 2021 PRNewswire -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. AcelRx or the Company NASDAQ: ACRX and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-04353, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AcelRx securities between March 17, 2020 and February 12, 2021, both dates inclusive the Class Period, seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10b and 20a of the Securities Exchange Act of 1934 the Exchange Act and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. 